Cardiac safety and potential efficacy: Two reasons for considering minocycline in place of azithromycin in COVID-19 management

Giovanni Diana; Rocky Strollo; Davide Diana; Mirko Strollo; Alfredo R. Galassi; Filippo Crea

doi:10.1093/ehjcvp/pvaa049

Cardiac safety and potential efficacy: Two reasons for considering minocycline in place of azithromycin in COVID-19 management

Giovanni Diana
, Rocky Strollo
, Davide Diana
, Mirko Strollo
, Alfredo R. Galassi
, Filippo Crea

Universita Campus Bio-Medico di Roma
University of Palermo
University of Naples Federico II

Risultato della ricerca: Contributo in rivista › Articolo

Abstract

N/A

Lingua originale	Inglese
pagine (da-a)	E53-E54
Rivista	EUROPEAN HEART JOURNAL. CARDIOVASCULAR PHARMACOTHERAPY
Volume	7
DOI	https://doi.org/10.1093/ehjcvp/pvaa049
Stato di pubblicazione	Pubblicato - 2021

Keywords

Anti-Bacterial Agents
Azithromycin
COVID-19
Humans
Minocycline

Accesso al documento

10.1093/ehjcvp/pvaa049

Altri file e collegamenti

Link a IRIS PubliCatt

Cita questo

@article{d2a41e86ae0e4efe86fc94a46421d347,

title = "Cardiac safety and potential efficacy: Two reasons for considering minocycline in place of azithromycin in COVID-19 management",

abstract = "N/A",

keywords = "Anti-Bacterial Agents, Azithromycin, COVID-19, Humans, Minocycline, Anti-Bacterial Agents, Azithromycin, COVID-19, Humans, Minocycline",

author = "Giovanni Diana and Rocky Strollo and Davide Diana and Mirko Strollo and Galassi, \{Alfredo R.\} and Filippo Crea",

year = "2021",

doi = "10.1093/ehjcvp/pvaa049",

language = "English",

volume = "7",

pages = "E53--E54",

journal = "EUROPEAN HEART JOURNAL. CARDIOVASCULAR PHARMACOTHERAPY",

issn = "2055-6837",

publisher = "Oxford : Oxford University Press",

}

TY - JOUR

T1 - Cardiac safety and potential efficacy: Two reasons for considering minocycline in place of azithromycin in COVID-19 management

AU - Diana, Giovanni

AU - Strollo, Rocky

AU - Diana, Davide

AU - Strollo, Mirko

AU - Galassi, Alfredo R.

AU - Crea, Filippo

PY - 2021

Y1 - 2021

N2 - N/A

AB - N/A

KW - Anti-Bacterial Agents

KW - Azithromycin

KW - COVID-19

KW - Humans

KW - Minocycline

KW - Anti-Bacterial Agents

KW - Azithromycin

KW - COVID-19

KW - Humans

KW - Minocycline

UR - http://hdl.handle.net/10807/203962

U2 - 10.1093/ehjcvp/pvaa049

DO - 10.1093/ehjcvp/pvaa049

M3 - Article

SN - 2055-6837

VL - 7

SP - E53-E54

JO - EUROPEAN HEART JOURNAL. CARDIOVASCULAR PHARMACOTHERAPY

JF - EUROPEAN HEART JOURNAL. CARDIOVASCULAR PHARMACOTHERAPY

ER -

Cardiac safety and potential efficacy: Two reasons for considering minocycline in place of azithromycin in COVID-19 management

Abstract

Keywords

Accesso al documento

Altri file e collegamenti

Fingerprint

Cita questo